Active, not recruitingPhase 1NCT04684108

SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies

Studying Plasma cell tumor

Last synced from ClinicalTrials.gov May 17, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Hangzhou Sumgen Biotech Co., Ltd.
Intervention: SG301(drug)
Enrollment: 61 enrolled
Eligibility: 18 years · All sexes
Timeline: 2021 – 2026

Study locations (14)

The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
Affiliated Beijing Chaoyang Hospital of Capital Medical University, Beijing, Beijing Municipality, China
Beijing Jishuitan Hostipal, Beijing, Beijing Municipality, China
Shenzhen Second People's Hospital, Shenzhen, Guangzhou, China
The Fourth Affiliated Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
Henan Cancer Hospital, Zhengzhou, Henan, China
Wuhan University Central South Hospital, Wuhan, Hubei, China
Xiangyang Central Hospital, Xiangyang, Hubei, China
Wuxi Central Hospital, Wuxi, Jiangsu, China
The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, China
Shengjing Hospital Affiliated to China Medical University, Shenyang, Liaoning, China
Qilu Hospital of Shandong University, Jinan, Shandong, China
Shanxi Norman Bethune Hospital, Taiyuan, Shanxi, China
The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04684108 on ClinicalTrials.gov

Other trials for Plasma cell tumor

Additional recruiting or active studies for the same condition.

See all trials for Plasma cell tumor →

← Back to all trials